Cue Biopharma, Inc.

CUENASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
25.39 USD
↘ 0.15 (0.59%)AT CLOSE (11:59 AM EDT)
25.13
↘ 0.27 (1.04%)
POST MARKET (AS OF 05:15 PM EDT)
Post Market
AS OF 05:15 PM EDT
25.13
↘ 0.27 (1.04%)
🔴Market: CLOSED

CUE is currently priced at $25.39. Our models show a "Sell" technical signal alongside a "Neutral" fundamental rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, CUE trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 26, 2026.

Open?$25.76
High?$26.75
Low?$24.60
Prev. Close?$25.54
Volume?82.6K
Avg. Volume?95.4K
VWAP?$25.42
Rel. Volume?0.87x
Bid / Ask
Bid?$21.30 × 100
Ask?$29.23 × 100
Spread?$7.93
Midpoint?$25.27
Valuation & Ratios
Market Cap?106.6M
Shares Out?4.2M
Float?94.7M
Float %?97.2%
P/E Ratio?N/A
P/B Ratio?4.94
EPS?-$4.65
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
29
Market Cap
107.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.cuebiopharma.com
Listed
2018-01-02
Address
40 GUEST STREET
BOSTON, MA 02135
Phone: 617-949-2680
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
77
Short Sent.?
78
Piotroski F-Score?2/9Weak
Altman Z-Score?-10.33Distress
Confidence?47%Low
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?0.29%Low
Short Interest?275.0K
Days to Cover?3.7
Free Float94.7M
Avg Daily Volume73.7K
Settlement Date2026-06-15
Financial Health
Current Ratio?3.57Strong
Quick Ratio?3.57Strong
Cash Ratio?2.22Strong
Debt/Equity?0.05Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
37
4.94FAIR▾
P/S?
Peers
100
S&P
47
3.26FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.0CHEAP▾
EV/Sales?
Peers
100
S&P
64
2.79CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-90.4%WEAK▾
ROA?
S&P
3
-63.2%WEAK▾
Cash Flow & Enterprise
FCF?$-24605000
Enterprise Value?$91.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist